Entergy Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Entergy Corporation trades at $102.8 (market cap $49.12B), while Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Entergy Corporation pays the higher dividend (2.49%). Which is the better fit depends on your goals — on Pluang, investors hold Entergy Corporation for 9 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ETR | REGN | |
|---|---|---|
Market Cap | $49.12B | $76.14B |
Volume | 2,228,388 | 500,239 |
Sector | Utilities | Health |
52-Week High | $117.91 | $852.03 |
52-Week Low | $91.19 | $557.73 |
Typical Hold Time | 9 Days | 107 Days |
Enterprise Value | $79.89B | $70.85B |
Dividend Yield | 2.49% | 0.51% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Trailing returns across standard periods
Latest headlines on both assets
Entergy is an energy company that operates regulated electric utilities and power generation businesses in the United States. Its generation portfolio includes nuclear, natural gas, and renewable resources.
Read more on ETR →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →